Inozyme Pharma, Inc. Profile

Industry

Biotechnology

Sector

Healthcare

Number of Employees

Inozyme Pharma's Business Model

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

About Inozyme Pharma

Website: https://www.inozyme.com

CEO (Chief Executive Officer): Dr. Douglas A. Treco Ph.D.

IPO date: 2020-07-24

Contact

Country: US

Address: 321 Summer Street

City: Boston

State: MA

Phone: 857 330 4340

Zip Code: 02210

Other

CIK: 0001693011

ISIN: US45790W1080

CUSIP: 45790W108

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.